Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BriDGe study, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Roche Diagnostics, all published on July 20, 2026.
Last mentioned: Jul 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BriDGe study, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Roche Diagnostics, all published on July 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Roche Diagnostics. Shared-story counts are live from our verified record — not editorial picks.
Roche Diagnostics' p-tau217 assay is being evaluated in a pragmatic trial across 50 Scottish GP practices, enrolling up to 500 patients. The BriDGe study could produce critical real-world evidence to support regulatory approval and companion diagnostic strategies for emerging Alzheimer's therapies.
Source: bournemouthecho.co.uk · oxfordmail.co.uk
Roche Diagnostics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
